Dermata Therapeutics Announces Results From Its DMT310 Phase 2b Acne Results Published In Journal Of The American Academy Of Dermatology
Portfolio Pulse from Benzinga Newsdesk
Dermata Therapeutics announced positive results from its DMT310 Phase 2b acne study, published in the Journal of the American Academy of Dermatology. The once-weekly topical treatment demonstrated significant improvements in all primary endpoints. FDA responses to the DMT310 End of Phase 2 meeting package are expected by the end of this month.
June 08, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Dermata Therapeutics' DMT310 Phase 2b acne study demonstrated significant improvements, potentially leading to positive FDA responses and increased investor interest.
The positive results from Dermata Therapeutics' DMT310 Phase 2b acne study indicate that the treatment is effective, which could lead to positive FDA responses and increased investor interest in the company. This is likely to have a positive short-term impact on the stock price of DRMA.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100